News of Note—Vetter and Nanoform expand and WuXi Biologics plant gets FDA nod

Financial market data. Image: Pixabay
(Pixabay)

> CDMO Vetter says the expansion of its facility in suburban Chicago is nearly complete. Release

> Vaccine producer Seqirus says for the 2019-2020 flu season, it will manufacture vaccines for all four flu strains recommended by WHO using its cell-based processes. Release 

> China has taken steps to overcome drug shortages in the country including fining some companies for market concentration. Story

> WuXi Biologics announced that its Drug Substance and Drug Product manufacturing facilities at Wuxi city successfully completed a seven-day FDA surveillance inspection by three inspectors for the production of Trogarzo, the first routine GMP inspection since the product's approval. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Helsinki, Finland-based Nanoform says it expects to begin producing drug product this year in a 600 square meter manufacturing plant it is building at Cultivator II in Viikki Life Science Park, Finland. Release

> Adare Pharmaceuticals, has an agreement with Egalet Corporation for technology that enables single-dose formulation of taste-masked, easy-to-swallow oral medications for the pediatric and geriatric populations. Release

> Coquí Radio Pharmaceuticals Corp. has received 206 acres in Oak Ridge, Tennessee, from the Department of Energy on which to build a dedicated medical isotope production facility to address the U.S. reliance on imported medical isotopes that are used for diagnosing and treating a variety of diseases. Release

Read more on

Suggested Articles

AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung…

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.